Edition:
United Kingdom

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

17.98USD
17 Jan 2018
Change (% chg)

$-1.76 (-8.92%)
Prev Close
$19.74
Open
$17.55
Day's High
$18.13
Day's Low
$17.12
Volume
1,607,122
Avg. Vol
421,201
52-wk High
$21.12
52-wk Low
$10.75

Select another date:

Tue, Jan 9 2018

BRIEF-Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018

* HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018

BRIEF-Alexion And Halozyme Enter License Agreement For ENHANZE Technology

* ALEXION AND HALOZYME ENTER LICENSE AGREEMENT FOR ENHANZE TECHNOLOGY Source text for Eikon: Further company coverage:

BRIEF-Halozyme reports Q3 EPS of $0.02

* Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S

BRIEF-Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex

* Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex with co's enhanze technology​

Halozyme to license drug delivery tech to Roche, Bristol-Myers

U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.

BRIEF-Halozyme licenses new Enhanze target for $30 mln upfront payment

* Halozyme licenses new enhanze target for $30 million upfront payment, future milestones and royalties

Halozyme to license drug delivery tech to Roche, Bristol-Myers

Sept 14 U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.

BRIEF-Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

* Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

BRIEF-Halozyme reports Q2 loss per share $0.23

* Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S

Select another date: